腹膜糖转运及钠-葡萄糖共转运蛋白2抑制剂在腹膜透析领域的研究进展  

Current developments in peritoneal glucose transport and sodium-glucose co-transporter 2 inhibitors during peritoneal dialysis

作　　者：杨帆[1] 刘聪慧 王小琪 刘小菁[1] 史亚男[1] 李忠心[1] Yang Fan;Liu Cong-hui;Wang Xiao-qi;Liu Xiao-jing;Shi Ya-nan;Li Zhong-xin(Department of Nephrology,Affiliated Beijing Luhe Hospital,Capital Medical University,Beijing 101149,China)

机构地区：[1]首都医科大学附属北京潞河医院肾病中心,北京101149

出　　处：《临床肾脏病杂志》2023年第11期946-950,共5页Journal Of Clinical Nephrology

摘　　要：钠-葡萄糖共转运蛋白(sodium-glucose co-transporter,SGLT)2抑制剂是目前临床广泛使用的新药物,已知SGLT2抑制剂可以通过阻断SGLT2减少近端肾小管细胞对葡萄糖的重吸收来降低2型糖尿病患者的血糖。同时,该药物可为糖尿病及非糖尿病患者带来显著的肾脏及心血管获益。腹膜透析患者的人腹膜间皮细胞可表达SGLT。关于SGLT2抑制剂在腹膜透析领域的研究已有体外或动物实验报道,提示接受PD治疗的患者应用SGLT2抑制剂,可减少腹膜葡萄糖吸收,可能延迟腹膜纤维化的进展。同时,腹膜寿命的延长及转运功能的维持有利于保证透析充分性,改善患者预后。但是SGLT2抑制剂在腹膜透析领域的应用尚未引起广泛关注。本文将就腹膜糖代谢及SGLT2抑制剂在腹膜透析领域的研究进展做一综述。As a novel widely used drug,sodium-glucose co-transporter(SGLT)2 inhibitor may lower blood glucose in type 2 diabetics through blocking SGLT2 to curtain glucose reabsorption in proxi-mal renal tubular cells.At the same time,this drug may bring significant renal and cardiovascular benefits to both diabetics and non-diabetics.Human peritoneal mesothelial cells(HPMCs)from peritoneal dialysis(PD)patients can express SGLT.Studies of SGLT2 inhibitors in PD have been reported in in vitro or ani-mal experiments.Using SGLT2 inhibitors in PD patients can reduce peritoneal glucose absorption and de-lay the progress of peritoneal fibrosis.At the same time,prolonged use of peritoneum and maintenance of transport function are conducive to ensuring dialysis adequacy and optimizing the prognosis.However,ap-plication of SGLT2 inhibitors during PD has not attracted extensive attention.This review focused upon the developments of peritoneal glucose metabolism and SGLT2 inhibitors during PD.

关 键 词：钠-葡萄糖转运蛋白质类 腹膜透析 腹膜间皮细胞 糖转运 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]